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Network meta-analysis: introduction and assumptions
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What is a Network Meta-analysis?
A B Pair-wise MA
A
CB
D
(a)
A C
B D
(b)
Indirect Comparisons
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Network Meta-analysis: loops
AKA: Mixed Treatment Comparison (MTC)
Multiple Treatment Comparison
Multiple Treatment Meta-analysis (MTM)
A
C
B
D
E
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Network Meta-analysis: loops
A
C
B
D
E
3
6
3
5
1
1
Number of trials added to edges
AKA: Mixed Treatment Comparison (MTC)
Multiple Treatment Comparison
Multiple Treatment Meta-analysis (MTM)
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Significance of LOOPS in NMA
The existence of “evidence loops” means that there is 
both DIRECT evidence and INDIRECT evidence on 
the same contrast
• More data, so estimates are more precise, more 
robust (less sensitive to any one source of data)
• Possible, and indeed necessary, to check 
“consistency” of the direct and indirect.
B
A
C
Red line represent DIRECT evidence on BC effect;
Black lines provide INDIRECT evidence on BC effect.
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When to do a NMA?
IF 
a) There are more than 2 treatments
AND
b) If all the trials had been on just two treatments (any two), you 
would have done a pair-wise MA
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Do you HAVE to do a NMA?
If you want to decide which is best out of >2: YES!
Suppose 3 treatments: A,B,C
They have been compared in B vs A, C vs A and C vs B trials
Separate meta-analyses have been done and we now have 
estimates 
Is that enough?   NO!
We need COHERENT ESTIMATES 
ˆ ˆ ˆ 
COH COH COH
AC AB BC
d d d= +
ˆ ˆ ˆ, ,
AB AC BC
d d d
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Coherent decisions
• Coherent decisions need coherent evidence
• Otherwise no way to decide which treatment is best
• NMA is just a method to find the coherent estimates  
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Coherent decisions
• Does it make sense to make decisions based on estimates of 
relative effect from separate meta-analyses?
• These estimates will not be consistent, yet we are still using them to 
make the decision.
• By stating we can use all evidence to make a decision, we are 
implicitly assuming that the evidence is consistent…
• And doing informal indirect comparisons without fully accounting for 
uncertainty
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Indirect comparisons: Bucher method
We have “direct” data on AB  and AC effects.
What is the BC effect?
   
   
ˆ ˆ ˆvar( )  var( ) var( )indirect direct direct
BC AC AB
d d d∴ = +
B
A
C
ˆ ˆ ˆindirect direct direct
BC AC AB
d d d= −
A B C
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Exercise 1. Indirect Comparisons
Outcome: mean difference (reduction in pain)
A B C
Comparison
Mean 
difference SE 95%CI
B vs A -2.3 0.45 (-3.18, -1.42)
C vs A -4.0 0.50 (-4.98, -3.02)
In the absence of a direct RCT, calculate the relative effect of treatment 
C vs B 
(assuming the patient populations included in the B vs A and the C vs A trials are comparable to 
each other and relevant to our target population)
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Exercise 1. Solution 
( )
Indirect estimate of C vs B:
ˆ ˆ ˆ   4.0 ( 2.3)
3.01,  0.39
1.7
With 95%CI 
Ind Dir Dir
BC AC AB
d d d= − = − − − =
− −
−
Comparison
Mean 
difference SE 95%CI
B vs A -2.3 0.45 (-3.18, -1.42)
C vs A -4.0 0.50 (-4.98, -3.02)
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Network meta-analysis
• A network meta-analysis will put together direct and indirect 
evidence to produce a coherent estimate using all the available, 
relevant, evidence.
( )3.01,  0.3
Indirect estimate of C vs B:
ˆ ˆ ˆ   1.7           95%CI 9
Ind Dir Dir
BC AC AB
d d d= − = −− −
What if we also had a trial of C vs B:
mean difference -1.8 95%CI (-3.66, 0.06)?
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Thrombolysis NMA: worked example 
SK
r-PA
t-PA
SK+t-PA
Acc t-PA
TNK
6 treatments - Streptokinase (SK), Tissue-plasminogen activator (t-PA), Accelerated tissue-
plasminogen activator  (At-PA), Tenecteplase (TNK), Reteplase (r-PA) 
14 trials. 15 possible pairwise comparisons
Boland et al, Health Technology Assessment, 2003
RCTs SK t-PA Acc t-PA Sk+tPA r-PA TNK
8  
1   
1  
1  
2  
1  
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Results: Thrombolysis – pairwise meta-analyses (fixed effects)
odds ratios (95%CI)
SK t-PA Acc t-PA t-PA+SK r-PA TNK
SK X 1.00
(0.94-1.06)
0.86
(0.78-0.94)
0.96
(0.87-1.05)
0.95
(0.79-1.12)
t-PA X
Acc t-PA X 1.12
(1.00-1.25)
1.02
(0.90-1.16)
1. 01
(0.88-1.14)
t-PA+SK X
r-PA X
TNK X
OR > 1 favours row-defining treatment
Note: all results from fixed effects analysis AND same direction of effects…
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Upper right: pair-wise ORs 95%CI
Lower left:  NMA ORs 95% CI
SK t-PA Acc t-PA t-PA+SK r-PA TNK
SK X 1.00
(0.94-1.06)
0.86
(0.78-0.94)
0.96
(0.87-1.05)
0.95
(0.79-1.12)
t-PA 1.00
(0.94-1.06)
X
Acc t-PA 0.87
(0.79-0.94)
0.87
(0.78-0.97)
X 1.12
(1.00-1.25)
1.02
(0.90-1.16)
1.01
(0.88-1.14)
t-PA+SK 0.96
(0.88-1.05)
0.96
(0.87-1.08)
1.11
(1.00-1.24)
X
r-PA 0.90
(0.80-1.01)
0.90
(0.79-1.03)
1.04
(0.94-1.16)
0.94
(0.81-1.08)
X
TNK 0.87
(0.75-1.01) 
0.87
(0.74-1.03)
1.01
(0.89-1.14)
0.90
(0.77-1.07)
0.96
(0.82-1.14) 
X
Upper diagonal: OR > 1 favours row-defining treatment
Lower diagonal: OR < 1 favours row-defining treatment
Introduction to NMA © University of Bristol
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SK t-PA Acc t-PA t-PA+SK r-PA TNK
SK X 1.00
(0.94-1.06)
0.86
(0.78-0.94)
0.96
(0.87-1.05)
0.95
(0.79-1.12)
t-PA 1.00
(0.94-1.06)
X
Acc t-PA 0.87
(0.79-0.94)
0.87
(0.78-0.97)
X 1.12
(1.00-1.25)
1.02
(0.90-1.16)
1.01
(0.88-1.14)
t-PA+SK 0.96
(0.88-1.05)
0.96
(0.87-1.08)
1.11
(1.00-1.24)
X
r-PA 0.90
(0.80-1.01)
0.90
(0.79-1.03)
1.04
(0.94-1.16)
0.94
(0.81-1.08)
X
TNK 0.87
(0.75-1.01) 
0.87
(0.74-1.03)
1.01
(0.89-1.14)
0.90
(0.77-1.07)
0.96
(0.82-1.14) 
X
Upper diagonal: OR > 1 favours row-defining treatment
Lower diagonal: OR < 1 favours row-defining treatment
Upper right: pair-wise ORs 95%CI
Lower left:  NMA ORs 95% CI
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Example: Early thrombolysis for AMI
RCTs SK t-PA Acc t-PA Sk+tPA r-PA TNK
8  
1   
1  
1  
2  
1  
6 treatments: Streptokinase (SK), Tissue-plasminogen activator (t-PA), Accelerated t-PA 
(Acc t-PA), Tenecteplase (TNK), Reteplase (r-PA) 
14 trials; 7 comparisons made; 15 possible pairwise comparisons
SK
r-PA
t-PA
SK+t-PA
Acc t-PA
TNK
Introduction to NMA © University of Bristol
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SK t-PA Acc t-PA t-PA+SK r-PA TNK
SK X 1.00
(0.94-1.06)
0.86
(0.78-0.94)
0.96
(0.87-1.05)
0.95
(0.79-1.12)
t-PA 1.00
(0.94-1.06)
X
Acc t-PA 0.87
(0.79-0.94)
0.87
(0.78-0.97)
X 1.12
(1.00-1.25)
1.02
(0.90-1.16)
1.01
(0.88-1.14)
t-PA+SK 0.96
(0.88-1.05)
0.96
(0.87-1.08)
1.11
(1.00-1.24)
X
r-PA 0.90
(0.80-1.01)
0.90
(0.79-1.03)
1.04
(0.94-1.16)
0.94
(0.81-1.08)
X
TNK 0.87
(0.75-1.01) 
0.87
(0.74-1.03)
1.01
(0.89-1.14)
0.90
(0.77-1.07)
0.96
(0.82-1.14) 
X
Upper right: pair-wise ORs 95%CI
Lower left:  NMA ORs 95% CI
Upper diagonal: OR > 1 favours row-defining treatment
Lower diagonal: OR < 1 favours row-defining treatment
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Example: Early thrombolysis for AMI*
RCTs SK t-PA Acc t-PA Sk+tPA r-PA TNK
8  
1   
1  
1  
2  
1  
6 treatments: Streptokinase (SK), Tissue-plasminogen activator (t-PA), Accelerated t-PA 
(Acc t-PA), Tenecteplase (TNK), Reteplase (r-PA) 
14 trials; 7 comparisons made; 15 possible pairwise comparisons
SK
r-PA
t-PA
SK+t-PA
Acc t-PA
TNK
Introduction to NMA © University of Bristol
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Probability treatment x is ‘best’: clinical effectiveness 
Ranks
Pr(best) Mean Median
95% 
CrI
1 SKA 0 5.27 5 (4, 6)
2 t-PA 0 5.07 5 (3, 6)
3 Acc t-PA 0.40 1.73 2 (1, 3)
4 t-PA + SK 0.01 4.14 4 (2, 6)
5 r-PA 0.16 2.73 3 (1, 5)
6 TNK 0.43 2.06 2 (1, 5)
• Caution: Pr(best) very 
sensitive to different levels 
of uncertainty.
• It is possible for a 
treatment to have the 
highest probability of 
being the best and also 
the highest probability of 
being the worst!
• Also useful to look at prob 
of being 2nd best,  3rd best 
etc
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Ranking probability of each treatment
rk[1] sample: 40000
1 2 4 6
    0.0
    0.2
    0.4
    0.6
rk[2] sample: 40000
1 2 4 6
    0.0
    0.1
    0.2
    0.3
    0.4
rk[3] sample: 40000
1 2 4 6
    0.0
    0.2
    0.4
    0.6
rk[4] sample: 40000
1 2 4 6
    0.0
    0.2
    0.4
    0.6
rk[5] sample: 40000
1 2 4 6
    0.0
    0.2
    0.4
    0.6
rk[6] sample: 40000
1 2 4 6
    0.0
    0.2
    0.4
    0.6
Introduction to NMA © University of Bristol
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Interpreting ranking plots
• Out of 40,000 iterations treatment 1 was never ranked first, i.e. 
Pr(treatment 1 is the best)=0
• It was ranked 4th a few times (approx 10%), so Pr(treatment 1 is 4th
best) ≈0.10
• NOTE: this is quite different from: “The prob that treatment 1 is the best 
4th line treatment is 10%” rk[1] sample: 40000
1 2 4 6
    0.0
    0.2
    0.4
    0.6
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Exercise 2. Interpreting ranking plots
A. Based on the ranking plots in the previous slides, and all other 
results presented, which thrombolytic treatment (or treatments) 
would you recommend and why?
(based only on clinical effectiveness)
B. If treatment X is the recommended first line treatment for a 
particular condition, how would we determine which is the best 
second line treatment?
Explain your reasons.
Introduction to NMA © University of Bristol
Workshop
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Exercise 2. Solution
A. Treatments 3 and 6 have the two highest probabilities of being 
best and 2nd best, so that overall they both have a high 
probability of being the top two treatments.
In addition the odds ratio of treatment 6 compared to 3 is 1.01 95%CrI 
(0.89-1.14) indicating no difference between them.
If everything else was equal (costs, side effects etc), we would probably 
recommend both treatments.
B. To decide which is the best 2nd line therapy, we would need 
evidence (RCTs) on patients who have failed on the first line 
treatment, which could be pooled in a NMA to determine the 
best second line treatment
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How wide should a network be?
• Start with the treatments “of interest”
• These should already have been determined in initial discussions / 
scoping
• Include ALL the trials in the target population between any pair of 
the treatments of interest. 
• Does this form a connected network?
• If so: that is the “base-case” network
Introduction to NMA © University of Bristol
Workshop
G-I-N September 2018 15
G-I-N 2018: Introduction to NMA for decision making 29
Adding a treatment to connect the network
If the network is NOT connected, are there other 
treatments (G) that can be used to connect the 
sub-networks ABC and XY?
A
B C
X Y
G
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All trials in enlarged network
• If an additional treatment is introduced to link networks, check 
whether there are other treatments that could also do the link, 
and include.
• Then include ALL the trials that link the enlarged set of treatments
Introduction to NMA © University of Bristol
Workshop
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Trial inclusion: multiple connectors
• If an additional treatment is introduced to link networks, check 
whether there are other treatments that could also do the link
• Then include ALL the trials that link the enlarged set of treatments
A
B C
X Y
G
H
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Exercise 3. Extended Thrombolysis Network
• ASPAC, UK, and PTCA were omitted from the Thrombolysis HTA
• ASPAC, UK are old treatments and no longer used. PTCA is used.
• Discuss which evidence you would include in a NMA to inform clinical guidelines
SK (1)
UK (8)
PTCA (7)
TNK (6)
r-PA (5)
SK + t-PA (4)
Acc t-PA (3)
t-PA (2)
ASPAC (9)
Introduction to NMA © University of Bristol
Workshop
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Adding in PTCA
SK (1)
PTCA (7)
TNK (6)
r-PA (5)
SK + t-PA (4)
Acc t-PA (3)
t-PA (2)
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Results: Adding in PTCA      (Caldwell, Ades & Higgins; 2005)
0.63
0.86
0.90 1.05
0.86
0.64
1.01
0.74
0.95 0.52
0.63
1.01 0.811.02
1.00 0.86 0.96
0.86 0.86 1.12
SK + t-PA r-PA TNK PTCASK t-PA Acc t-PA
SK **
t-PA **1.00
Acc t-PA **
SK + t-PA **0.96 1.120.96
r-PA **0.940.90
TNK **
PTCA **0.74
0.96
0.71
0.90
0.66
CI: (0.64 – 1.02) 
CI: (0.61 – 0.89) 
Introduction to NMA © University of Bristol
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Probability treatment x is best: clinical effectiveness 
(Caldwell, DM. Ades, AE. & Higgins, JPT; BMJ 2005)
Treatment
% 35 mortality
Mean (95%CrI)
Probability Best
SK 6.7 (5.7, 7.7) 0%
t-PA 6.7 (5.7, 7.8) 0%
Acc t-PA 5.8 (4.9, 6.8) 0%
SK + t-PA 6.5 (5.4, 7.6) 0%
R-PA 6.1 (5.0, 7.2) 0%
TNK 5.8 (4.7, 7.1) 0.4%
PTCA 4.4 (3.5, 5.3) 99.6%
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What have we assumed?
• NMA assumes that the direct and 
indirect evidence “agree”
• True effects must be consistent
• … however data may not be
• must check for this
B
C
A
 
AC AB BC
θ θ θ= +
Introduction to NMA © University of Bristol
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65m
20m
45m
 
AC AB BC
θ θ θ= +
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Consistent
-2 -1 0 1 2
0
.0
0
.5
1
.0
1
.5
log-odds ratio
D
e
n
s
it
y
direct
full MTC
MTC excl. directindirect
NMA
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Possibly inconsistent?
-0.5 0.0 0.5 1.0
0
2
4
6
8
1
0
log-odds ratio
D
e
n
s
it
y
direct
full MTC
MTC excl. directindirect
N A
G-I-N 2018: Introduction to NMA for decision making 40
Inconsistent
0.0 0.5 1.0 1.5 2.0 2.5
0
1
2
3
4
5
6
7
log-odds ratio
D
e
n
s
it
y
direct
full MTC
MTC excl. directindirect
NMA
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When might consistency assumption fail?
• If trials differ in patients populations & protocols 
• Intervention A differs in AB trials and AC trials e.g. lumping over dose, different 
controls (waitlist, pill placebo, etc), change in standard care over time …
• Sicker patients included in AB trials than AC trials
• Differences in study conduct (outcome measures, risk of bias etc.)
• … ie differences in treatment effect-modifiers
• Same as heterogeneity in pairwise M-A
• CANNOT check consistency in a simple indirect comparison, but can with 
NMA if there are loops of evidence
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Chou et al, Lancet 2006, 368, 1503-15 
Trials of HAART regimes for HIV
A: 2 NRTIs 
B: 2 NRTIs + PI
C: 2 NRTIs + NNRTI
“Indirect evidence on d
BC
inconsistent with direct evidence from BC trials”
“Indirect Comparisons unreliable for complex interventions like HAART” 
Introduction to NMA © University of Bristol
Workshop
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Dangers of “Lumping”
A: 2 NRTIs ,   B: 2 NRTIs + PI,   C: 2 NRTIs + NNRTI
BUT the NRTIs in the AB trials were DIFFERENT from the NRTIs in the BC trials. 
When the comparison was restricted to trials with the SAME NRTI regimes, 
the “inconsistency” no longer statistically significant.  
Similar findings reported by Song et al :  “lumping” over aspirin doses.
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Thrombolysis: Including older treatments ASPAC and UK
SK (1)
UK (8)
PTCA (7)
TNK (6)
r-PA (5)
SK + t-PA (4)
Acc t-PA (3)
t-PA (2)
ASPAC (9)
Introduction to NMA © University of Bristol
Workshop
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0.0 0.5 1.0 1.5 2.0 2.5
0
1
2
3
4
5
6
7
log-odds ratio
D
e
n
s
it
y
direct
full MTC
MTC excl. direct
• Direct information 
contradicts indirect
• p-value = 0.001
• Indirect evidence from very 
large trials dominates direct 
evidence from smaller trials
Clear inconsistency
Indirect
ASPAC vs Acc t-PA
NMA
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How to avoid inconsistency?
• Careful thought given to PICOS
• Population: well-defined inclusion/exclusion criteria … not too 
broad
• Interventions … avoid “lumping” 
• Comparators … keep different control conditions distinct
• Outcomes … should be similar eg follow-up time, same units
• Study design … exclude studies at high risk of bias
Introduction to NMA © University of Bristol
Workshop
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Enuresis Overview of Reviews: Failure to achieve 14 dry nights
X Y Relative Risk
Y rel to X, 
95% CI
Nothing  Alarm 0.38 0.33 – 0.45
Dry Bed Training Alarm 1.33 0.79 – 2.24
Desmopressin Alarm  0.71 0.50 – 0.99
Imipramine Alarm 0.73 0.61 – 0.88
Cognitive Alarm 0.68 0.52 – 0.90
Nothing Cognitive 0.69 0.55 – 0.85
Nothing Dry Bed Training 0.82 0.66 – 1.02
Nothing DBT + alarm 0.17 0.11 – 0.28
Nothing Dicolfenac 0.52 0.38 – 0.70
Nothing Imipramine 0.77 0.72 – 0.83
XY
θ
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Exercise: Enuresis network
• Can the data presented in overview Table lead to a coherent 
decision, as it stands?
No treatment Alarm
Cognitive
Therapy
Imipramine Dry bed training
Desmopressin
Diclofenac Dry bed training
+ Alarm
Introduction to NMA © University of Bristol
Workshop
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Solution
• No!
• Alarm vs Nothing RR=0.38
• Dry Bed Training vs Nothing RR=0.82
• Suggests Alarm is better than Dry Bed Training
• Alarm vs Dry Bed Training RR=1.33
• Suggests Dry Bed Training is better than Alarm
• Even if direction of effect unchanged, the strength and size of effect 
can be different
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Exercise 4: Enuresis
• Inspect handout with populations and settings for the studies 
included in the Enuresis example for Alarm vs No Treatment and 
Imipramine vs No Treatment
• Do you think it is sensible to combine these studies in a NMA?
• What might you do differently?
Introduction to NMA © University of Bristol
Workshop
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What to do if inconsistency identified?
• Try to explain it …
• Check the data!
• Re-visit inclusion/exclusion of studies, intervention definitions and 
outcomes
• Consider adjusting for effect modifiers
• How robust are recommendations to potential bias in the evidence?
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Threshold analysis
Assessing the robustness of decisions to changes in the evidence
Introduction to NMA © University of Bristol
Workshop
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Motivation – Thrombolytics Example
Treatment
Log odds ratio 
(95% CrI)
1 SK 0
2 t-PA 0.00  (0.06, 0.06)
3 Accelerated t-PA -0.16  (-0.24, -0.07)
4 SK plus t-PA -0.04  (-0.13, 0.05)
5 r-PA -0.11  (-0.23, 0.01)
6 TNK -0.15  (-0.30, 0.00)
7 PTCA -0.46  (-0.66, -0.26)
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Motivation
How robust are the results to bias?
• Evidence quality is only half the story
Quality
Low High
Influence
Low
High
Introduction to NMA © University of Bristol
Workshop
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The Threshold Method
We create an invariant interval for a data point:
+ve threshold–ve threshold
Invariant Interval
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The Threshold Method
We can do this at two “levels”:
• Study level
• Thresholds for each individual study estimate
• Contrast level
• Thresholds for combined body of evidence on a contrast
• Highly flexible due to an approximation step
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Example: Thrombolytics
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Example: Thrombolytics – contrast level
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Example: Thrombolytics – study level
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Example: Thrombolytics – study level
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Exercise: Headaches clinical guideline
Treatment
Mean change in 
headache days per 
month (95% CrI)
1 Placebo 0
2 Telmisartan -0.51 (-2.32, 1.27)
3 Amitriptyline -1.14 (-2.45, 0.16)
4 Divalproex Sodium 0.13 (-0.99, 1.23)
5 Gabapentin 0.00 (-1.60, 1.58)
6 Topiramate -1.04 (-1.52, -0.58)
7 Propranolol -1.19 (-2.20, -0.20)
8 Propranolol/Nadolol -0.60 (-1.65, 0.45)
(NICE CG151.1, 2015)
Minimal Clinically Important Difference 
(MCID) = 0.5 days per month
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Exercise 5. Headaches clinical guideline
For the contrast and study level plots in turn:
• Are there any contrasts/studies that the decision is not sensitive to?
• Are there any that the decision is sensitive to?
What do you conclude about the robustness of the treatment decision?
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Exercise 5. Headaches clinical guideline – contrast level
Exercise 5. Headaches clinical guideline – study level
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Conclusions
• Threshold analysis provides insight into the effects of bias adjustment on treatment 
decisions
• We can have more confidence in recommendations where thresholds are large
• We can focus attention on the quality of decision-sensitive trials and contrasts
• More complex analyses can investigate specific concerns in the evidence, e.g. in groups 
of studies or treatments
• Can be used with a range of decision rules or for decisions based on cost-effectiveness
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